#1; D1 M #2; #1; #2; MF #1; MF #2. B. GVP. MFs for the 3R4F 3R4F THS2.2 GEF+DMSO GEF+DMSO PBS-treated control in tests #1 and #2 were 97.43 and 68.20 mutants/106 viable cells, respectively. D1 M THS2.2 #1; D1 M #2; #1; #2; MF #1; MF #2. 3R4F 3R4F THS2.2 GEF+PBS GEF+PBS A B Supplementary Material, Figure C: The mutagenic responses induced by aerosol fractions derived from THS2.2 variants and 3R4F in the 4 h -S9 treatment condition in two independent tests. A. TPM from THS2.2 D2 Regular and 3R4F. MFs for the DMSO-treated controls in tests #1 and #2 were 99.52 ± 19.21 and 112.81 ± 23.41 mutants/106 viable cells, respectively. D2 #1; D2 #2; #1; #2; MF #1; 3R4F 3R4F THS2.2 THS2.2 GEF+DMSO MF #2. B. GVP from THS2.2 D1 M and 3R4F. MFs for the PBS-treated control(s) in tests #1 and #2 GEF+DMSO were 122.33 and 94.10 ± 26.37 mutants/106 viable cells, respectively. D1 M #1; D1 M #2; 3R4F THS2.2 THS2.2 #1; #2; MF #1; MF #2. 3R4F GEF+PBS GEF+PBS Supplementary Material, Figure D: Mainstream aerosol from THS2.2 compared to the mainstream smoke HPHCs from the 3R4F reference cigarette (constituent levels set at 100%) and on a per-mg nicotine basis under the Health Canada Intense (HCI) machine-smoking regimen (when one value or more was below the LOQ, the results were not presented in the graphs).
#1; THS2.2 D1 M #2; 3R4F #1; 3R4F #2; GEF+DMSO MF #1; GEF+DMSO MF #2. B. GVP. MFs for the PBS-treated control in tests #1 and #2 were 97.43 and 68.20 mutants/106 viable cells, respectively. THS2.2 D1 M #1; THS2.2 D1 M #2; 3R4F #1; 3R4F #2; GEF+PBS MF #1; GEF+PBS MF #2. A B Supplementary Material, Figure C: The mutagenic responses induced by aerosol fractions derived from THS2.2 variants and 3R4F in the 4 h -S9 treatment condition in two independent tests. A. TPM from THS2.2 D2 Regular and 3R4F. MFs for the DMSO-treated controls in tests #1 and #2 were 99.52 ± 19.21 and 112.81 ± 23.41 mutants/106 viable cells, respectively. THS2.2 D2 #1; THS2.2 D2 #2; 3R4F #1; 3R4F #2; GEF+DMSO MF #1; GEF+DMSO MF #2. B. GVP from THS2.2 D1 M and 3R4F. MFs for the PBS-treated control(s) in tests #1 and #2 were 122.33 and 94.10 ± 26.37 mutants/106 viable cells, respectively. THS2.2 D1 M #1; THS2.2 D1 M #2; 3R4F #1; 3R4F #2; GEF+PBS MF #1; GEF+PBS MF #2. Supplementary Material, Figure D: Mainstream aerosol from THS2.2 compared to the mainstream smoke HPHCs from the 3R4F reference cigarette (constituent levels set at 100%) and on a per-mg nicotine basis under the Health Canada Intense (HCI) machine-smoking regimen (when one value or more was below the LOQ, the results were not presented in the graphs).